Jul 28, 2025
In this episode, we focus on the history of researchers discovering the clinical applicability of the IL 23/17 axis, with a particular emphasis on psoriasis, psoriatic arthritis and axial SpA
- Intro 0:15
- In this episode 0:27
- Leonard Calabrese, DO, is listening! 1:07
- Recap of last episode 3:23
- Putting the pieces together 5:32
- Quick overview of this science heavy episode 6:27
- What is psoriasis? 7:42
- Immunosuppressants for psoriasis/ Throwing meds at people and seeing what happens 10:20
- In the modern world of 1986 – olive oil placebo trial 11:45
- A quick aside into fungi 12:44
- What kind of T-cells are involved here? 16:50
- The TH-1 hypothesis 18:31
- IL-23 and IL-17 are doing something 19:38
- Going back to the drawing board in 2004 20:12
- p40 + p19 = IL-23 21:08
- IL-23 via minicircle DNA in mice 23:09
- Brand new and shiny TH-17 25:30
- The family of IL-17 26:40
- What do we know about IL-17 and psoriasis? 27:17
- IL-17A vs IL-17F in mouse studies 27:42
- Finding the difference between IL-17A and IL-17F in humans 28:30
- What exactly is IL-17 doing? 29:51
- The articular manifestations of psoriatic arthritis 31:13
- Spondylarthritis and the IL 23/17 axis 34:10
- T-cells we haven’t talked about 35:49
- Summary of this episode 39:17
- Thanks for listening 41:38
We’d love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum.
References:
Bashyam H. J Exp Med. 2007;doi:10.1084/jem.2042fta
Bjerke R J. Acta Derm Venereol. 1982;PMID:6179355
Cargill M, et al. Am J Hum Genet. 2007;doi:10.1086/511051
Chan J R, et al. J Exp Med. 2006;doi:10.1084/jem.20060244
Cuthbert R J, et al. Ann Rheum Dis. 2019;doi:10.1136/annrheumdis-2019-215210
Ellis C N, et al. JAMA. 1986;doi:10.1001/jama.1986
Ettehadi P, et al. Clin Exp Immunol. 1994;doi:10.1111/j.1365-2249.1994.tb06244.x
Furue M, et al. Int J Mol Sci. 2020;doi:10.3390/ijms21041275
Gooderham M J, et al. J Eur Acad Dermatol Venereol. 2018;doi:10.1111/jdv.14868
Lee E, et al. J Exp Med. 2004;doi:10.1084/jem.20030451
Leonardi C L, et al. Lancet. 2008;doi:10.1016/S0140-6736(08)60725-4
Mease P J, et al. Lancet. 2000;doi:10.1016/S0140-6736(00)02530-7
Menon B, et al. Arthritis Rheumatol. 2014;doi:10.1002/art.38376
Moos S, et al. J Invest Dermatol. 2019;doi:10.1016/j.jid.2019.01.006
Muelle W, et al. N Engl J Med. 1979;doi:10.1056/NEJM197909063011016
Papp K A, et al. Lancet. 2008;doi:10.1016/S0140-6736(08)60726-6
Reinhardt A, et al. Arthritis Rheumatol. 2016;doi:10.1002/art.39732
Sherlock J P, et al. Nat Med. 2012;doi:10.1038/nm.2817
Tribe H T. Mycologist. 1998;doi:10.1016/S0269-915X(98)80100-6
Yawalkar N, et al. J Invest Dermatol. 1998;doi:10.1046/j.1523-1747.1998.00446.x
Zaba L C, et al. J Allergy Clin Immunol. 2009;doi:10.1016/j.jaci.2009.08.046
Disclosures: Brown reports no relevant financial disclosures.